Search Results - "Hoog, Meredith"

EPR24-109: Intentional Weight Loss and Associated Cancer Incidence Among Patients With Overweight or Obesity: A Systematic Literature Review by Liao, Chi-Yin, Sheffield, Kristin M, Hoog, Meredith M, Schapiro, David, Keni, Raghuvir, Gathirua-Mwangi, Wambui Grace, Kan, Hong

Get more information

The Health Care Resource Utilization and Costs Among Patients With Type 2 Diabetes and Either Cardiovascular Disease or Cardiovascular Risk Factors An Analysis of a US Health Insurance Database by Meyers, Juliana, Hoog, Meredith, Mody, Reema, Yu, Maria, Davis, Keith

“…Health care costs and cardiovascular (CV) outcomes were evaluated among US patients with type 2 diabetes (T2D) and cardiovascular disease (CVD) or CV risk…”
Get full text

Long‐term cost‐effectiveness analysis of tirzepatide versus semaglutide 1.0 mg for the management of type 2 diabetes in the United States by Valentine, William J., Hoog, Meredith, Mody, Reema, Belger, Mark, Pollock, Richard

“…Aim To evaluate the long‐term cost‐effectiveness of tirzepatide (5, 10 and 15 mg doses), a novel glucose‐dependent insulinotropic polypeptide (GIP) and…”
Get full text

92-LB: Higher Adherence and Persistence for Dulaglutide Compared with Oral Semaglutide at Six-Months Follow-Up with U.S. Real-World Data by PACZKOWSKI, ROSIRENE, HOOG, MEREDITH, PELESHOK, JENNIFER, YU, MARIA, HUANG, AHONG, LIMONE, BRENDAN, MANJELIEVSKAIA, JANNA

“…A retrospective, observational analysis of administrative claims data from the IBM MarketScan Databases assessed adherence and persistence among GLP-1 RA naive…”
Get full text

Long‐term cost‐effectiveness analysis of tirzepatide versus semaglutide 1.0mg for the management of type 2 diabetes in the United States by Valentine, William J, Hoog, Meredith, Mody, Reema, Belger, Mark, Pollock, Richard

“…AimTo evaluate the long‐term cost‐effectiveness of tirzepatide (5, 10 and 15 mg doses), a novel glucose‐dependent insulinotropic polypeptide (GIP) and…”
Get full text

Modeling Outcomes of Tirzepatide Versus Lifestyle Modification for Overweight and Obesity by Hoog, Meredith, Kan, Hong, Hankosky, Emily, Deger, Kristen, Sorensen, Sonja, Mojdami, Donna, Bae, Jay, Harris, Mackenzie, Ward, Jennifer, White, Benjamin

Get full text

Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: An adjusted indirect treatment comparison by Vadher, Karan, Patel, Hiren, Mody, Reema, Levine, Joshua A., Hoog, Meredith, Cheng, Alice YY, Pantalone, Kevin M., Sapin, Hélène

“…Aim To conduct an adjusted indirect treatment comparison (aITC) of the efficacy of tirzepatide 5/10/15 mg versus semaglutide 2 mg in patients with type 2…”
Get full text

Association of Dulaglutide Initiation Timing With Treatment Patterns and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus in the United States by Hoog, Meredith, Smith, Joseph L., Yu, Maria, Peleshok, Jennifer, Mody, Reema, Grabner, Michael

“…To describe clinical characteristics and treatment outcomes for early or late initiation of dulaglutide therapy in patients with type 2 diabetes. This…”
Get full text

Tirzepatide 10 and 15 mg vs semaglutide 2.0 mg: A long-term cost-effectiveness analysis in patients with type 2 diabetes in the United States by Mody, Reema, Valentine, William J, Hoog, Meredith, Sharland, Helen, Belger, Mark

“…Tirzepatide is a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist approved for type 2 diabetes (T2D) treatment…”
Get full text

649-P: Impact of Early Initiation of Dulaglutide on A1C in Patients with Type 2 Diabetes by HOOG, MEREDITH, SMITH, JOSEPH L., YU, MARIA, PELESHOK, JENNIFER, MODY, REEMA, GRABNER, MICHAEL

“…This retrospective, observational study assessed glycemic control over a 6-month follow-up among patient cohorts with T2D who initiated dulaglutide (DU) 0.75…”
Get full text

Efficacy of tirzepatide 5, 10 and 15mg versus semaglutide 2 mg in patients with type 2 diabetes: An adjusted indirect treatment comparison by Vadher, Karan, Patel, Hiren, Mody, Reema, Levine, Joshua A, Hoog, Meredith, Cheng, Alice YY, Pantalone, Kevin M, Sapin, Hélène

“…AimTo conduct an adjusted indirect treatment comparison (aITC) of the efficacy of tirzepatide 5/10/15 mg versus semaglutide 2 mg in patients with type 2…”
Get full text

Glycemic and Economic Outcomes in Elderly Patients with Type 2 Diabetes Initiating Dulaglutide Versus Basal Insulin in a Real-World Setting in the United States: The DISPEL-Advance Study by Hoog, Meredith, Paczkowski, Rosirene, Huang, Ahong, Halpern, Rachel, Buysman, Erin, Stackland, Sydnie, Zhang, Yiran, Wangia-Dixon, Ruth

“…Introduction Treatments like glucagon-like peptide-1 receptor agonists carry low hypoglycemia risk and are recommended for elderly patients with type 2…”
Get full text

Glycemic and Cost Outcomes among Hispanic/Latino People with Type 2 Diabetes in the USA Initiating Dulaglutide versus Basal Insulin: a Real-World Study by Hoog, Meredith, Maldonado, Juan M., Wangia-Dixon, Ruth, Halpern, Rachel, Buysman, Erin, Gremel, Garrett W., Huang, Ahong, Konig, Manige

“…Introduction Optimal glycemic management after diabetes onset remains a challenge in Hispanic/Latino adults with type 2 diabetes (T2D), often resulting in poor…”
Get full text

Comparison of Recommendations and Use of Cardiovascular Risk Equations by Health Technology Assessment Agencies and Clinical Guidelines by Betts, Marissa Blieden, Milev, Sandra, Hoog, Meredith, Jung, Hyosung, Milenković, Dušan, Qian, Yi, Tai, Ming-Hui, Kutikova, Lucie, Villa, Guillermo, Edwards, Christine

“…To identify risk equations for cardiovascular diseases (CVDs) in primary and secondary prevention settings that are used or recommended by health technology…”
Get full text

LBSUN319 Characteristics And Treatment Patterns Of Hispanic/latino Patients Initiating First Injectable Glp-1ra Or Basal Insulin by Hoog, Meredith, Maldonado, Juan M, Halpern, Rachel, Dhangar, Indu, Buysman, Erin, McNiff, Kim, Konig, Manige

“…Abstract Hispanic/Latino (H/L) adults in the United States have greater prevalence of T2D and diabetes-related complications compared to non-Hispanic/Latinos…”
Get full text

FRI638 Glycemic And Cost Outcomes In Hispanic/Latino People With Type 2 Diabetes Initiating Dulaglutide Or Basal Insulin In The US by Hoog, Meredith, Maldonado, Juan, Wangia-Dixon, Ruth, Halpern, Rachel, Buysman, Erin, Gremel, Garrett, Huang, Ahong, Konig, Manige

“…Abstract Disclosure: M. Hoog: Employee; Self; Eli Lilly & Company. Stock Owner; Self; Eli Lilly & Company. J. Maldonado: Employee; Self; Eli Lilly & Company…”
Get full text

Systematic review of therapy used in relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma by Galaznik, Aaron, Huelin, Rachel, Stokes, Michael, Guo, Yelan, Hoog, Meredith, Bhagnani, Tarun, Bell, Jill, Shou, Yaping

“…To identify real-world evidence on outcomes from therapies for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), we…”
Get full text

COMPARISON OF THE USE OF CARDIOVASCULAR RISK EQUATIONS BY HEALTH TECHNOLOGY ASSESSMENT BODIES AND CLINICAL GUIDELINES by Milev, Sandra, Blieden, Marissa, Jung, Hyosung, Hoog, Meredith, Qian, Yi, Edwards, Christine, Villa, Guillermo, Kutikova, Lucie, Ward, Alexandra, Beaubrun, Anne

“…Background: Health technology assessment (HTA) bodies consider cost-effectiveness in their value assessment frameworks and use cardiovascular disease (CV) risk…”
Get full text

Systematic Review of Therapy Used in Relapsed or Refractory Diffuse Large B-Cell Lymphoma by Galaznik, Aaron, Bell, Jill A, Hoog, Meredith M, Stokes, Michael E, Steenrod, Anna W, Knopf, Kevin B, Seal, Brian, Shou, Yaping

“…Non-Hodgkin's lymphoma is a heterogeneous group of diseases originating in the lymphoid system. The most common subtype, constituting up to 40% of all cases…”
Get full text